表皮生长因子受体突变与非小细胞肺癌脑转移的相关性研究进展  

Relationship between EGFR mutation and brain metastases in non-small cell lung cancer

作　　者：方亭文 曾璐琳 卢凯华[1] FANG Tingwen;ZENG Lulin;LU Kaihua(Department of Oncology,the First Affiliated Hospital of Nanjing Medical University,Nanjing 210029,China)

机构地区：[1]南京医科大学第一附属医院肿瘤科,江苏省南京市210029

出　　处：《实用老年医学》2025年第3期303-307,共5页Practical Geriatrics

摘　　要：肺癌位居全国老年人群致死恶性肿瘤的第1位。脑转移是造成肺癌病人较差预后的重要原因。非小细胞肺癌(NSCLC)是肺癌中的常见类型。此综述旨在深入探讨NSCLC病人中表皮生长因子受体(EGFR)突变与脑转移间的相关性,及存在脑转移的EGFR突变NSCLC病人的治疗方案,着重探讨了EGFR酪氨酸激酶抑制剂(EGFR-TKI)的靶向治疗新进展。Lung cancer ranks as the leading cause of cancer-related mortality among the elderly population.Brain metastases represent a significant factor contributing to the poor prognosis of the patients with lung cancer.Non-small cell lung cancer(NSCLC)is a common subtype of lung cancer.This review aims to comprehensively examine the correlation between epidermal growth factor receptor(EGFR)mutations and the occurrence of brain metastases in NSCLC patients,as well as the treatment strategies for those with EGFR-mutant NSCLC who present with brain metastases,especially the targeted therapy provided by the latest epidermal growth factor receptor tyrosine kinase inhibitors(EGFR-TKIs).

关 键 词：非小细胞肺癌 脑转移 表皮生长因子受体突变 

分 类 号：R734.2[医药卫生—肿瘤]